Clinical Trial Update: First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating thymosin alpha-1 in combination with standard therapy as first-line treatment for patients with EGFR-mutant non-small cell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Thymosin alpha-1 (thymosin alpha-1)

Snippet

Sponsor: SciClone Pharmaceuticals | Conditions: EGFR Mutation Positive Non Small Cell Lung Cancer | Phase 1, Phase 2 | Status: UNKNOWN